Median Technologies is a French healthcare technology company focused on medical imaging, artificial intelligence and cancer diagnosis. Its business combines an imaging services operation with the development of AI-powered Software as a Medical Device (SaMD).
The company operates through two important areas. Its iCRO business provides central imaging and AI-powered image analysis services for pharmaceutical and biotechnology companies running clinical trials. At the same time, Median is developing its eyonis® portfolio, designed to support earlier diagnosis of serious diseases including lung and liver cancer.
This combination makes Median Technologies different from a conventional biotechnology company. Its existing iCRO operation provides revenue, while eyonis® represents a potentially significant future growth opportunity.
Median Technologies Bourse: Listing and Share Information
For investors searching for Median Technologies bourse, the key market identifier is ALMDT.
Median Technologies is listed on Euronext Growth, with ISIN FR0011049824. The company also has warrants traded under the ticker MDTBS.
The stock has experienced considerable volatility, which is not unusual for a smaller healthcare technology company where future growth depends partly on product commercialization and regulatory progress.
As of September 4, 2026, ALMDT closed at approximately €4.11. On September 7, 2026, market data showed the stock trading around the €4 level during the session.
For context, the stock’s 52-week range was approximately €2.63 to €7.27, illustrating how widely the market valuation has moved during the period.
Median Technologies Share Price Snapshot
| Indicator | Recent figure |
|---|---|
| Ticker | ALMDT |
| Exchange | Euronext Growth |
| ISIN | FR0011049824 |
| September 4, 2026 close | ~€4.11 |
| 52-week range | ~€2.63–€7.27 |
| Market capitalization | ~€156.7 million |
| Next estimated earnings date | September 17, 2026 |
Market figures can change throughout the trading day, so investors should verify the latest quotation before making decisions.
Recent ALMDT Share Price Performance
Median Technologies has remained a volatile stock in 2026.
The share closed at €4.68 on August 21 before moving lower through late August and early September. By September 4, it had closed at €4.11.
The longer-term picture is more mixed. Market data showed the stock up roughly 34% over one year as of September 4, while it remained substantially below its five-year level.
This highlights an important point for anyone researching Median Technologies bourse: the stock should not be evaluated solely from its latest daily movement. Its valuation is closely linked to expectations surrounding commercial growth, regulatory achievements, financing and the future potential of its medical AI products.
2025 Financial Performance
Median Technologies entered 2026 with improving operational momentum.
For full-year 2025, the company reported revenue of approximately €23.4 million, while its iCRO order backlog reached €76.6 million at December 31, 2025. Cash and cash equivalents stood at €18.2 million at the end of the year.
One encouraging development was the reduction in operating losses. Median reported a 28% year-over-year reduction in operating loss for 2025, reflecting efforts to improve cost discipline and operating efficiency.
The backlog is particularly important because it gives investors a view of future contracted activity. A growing backlog does not automatically translate into immediate profits, but it can provide greater revenue visibility for the business.
Stronger Momentum in the First Half of 2026
The company’s performance strengthened further during the first half of 2026.
Median reported €11.8 million in iCRO revenue for the first six months of the year, compared with €11.3 million in the first half of 2025. That represented growth of approximately 4.4%.
More significantly, its iCRO order backlog reached a record €82.4 million at June 30, 2026, up 15.6% from the same point in 2025.
The company’s financial position also changed substantially. Following a successful €50 million capital increase, Median reported cash and cash equivalents of €60.8 million at June 30, 2026. The company said this extended its cash runway through the first half of 2028, with further potential extension if certain outstanding warrants are exercised.
This financing gives Median greater room to commercialize its technologies and continue developing its product pipeline.
Why eyonis® LCS Matters
One of the biggest developments behind the Median Technologies investment story is eyonis® LCS, an AI-powered medical device designed for lung cancer screening.
In 2026, the product achieved two important regulatory milestones. It received FDA 510(k) clearance in the United States and subsequently obtained CE marking in Europe. The CE marking allows commercialization across the European Economic Area under the applicable medical-device framework.
These approvals are important because regulatory clearance is a necessary step before broad commercial adoption.
Median has also been working on commercialization in the United States and expanding its eyonis® portfolio. Other development areas include eyonis® IPN, focused on incidental pulmonary nodules, and eyonis® HCC, targeting hepatocellular carcinoma.
If these technologies achieve meaningful commercial adoption, they could eventually become an important additional growth engine for the company.
What Could Drive the Stock Higher?
Several factors could influence the future performance of ALMDT.
1. Commercialization of eyonis® LCS
Regulatory approval is only one part of the process. Actual adoption by healthcare providers, screening programs and commercial partners will be crucial.
2. Continued iCRO Growth
The record €82.4 million backlog provides a strong base of contracted activity. Continued growth in pharmaceutical and biotechnology demand for imaging services could support revenue expansion.
3. Expansion Beyond Oncology
Median has begun expanding its imaging capabilities into therapeutic areas beyond oncology, including central nervous system and musculoskeletal clinical trials. This could increase the addressable market for its iCRO operation.
4. Improved Operating Leverage
The company is integrating AI more deeply into imaging workflows. If these improvements increase productivity while maintaining service quality, they could contribute to stronger profitability over time.
Key Risks for Investors
The potential upside comes with significant risks.
Profitability remains a major issue. Median continues to operate with losses, meaning investors are relying partly on future growth rather than established earnings.
Dilution is another consideration. The company has raised substantial capital, and outstanding warrants could result in additional shares being issued if exercised. Median reported approximately 12 million such warrants outstanding at June 30, 2026.
Commercial execution also matters. FDA clearance and CE marking do not guarantee rapid market adoption. Revenue from eyonis® will depend on commercialization, customer adoption and reimbursement or healthcare-system dynamics.
Finally, ALMDT’s relatively small market capitalization means the share price can react sharply to corporate announcements, financial results and changes in investor expectations.
Median Technologies Bourse Outlook
The outlook for Median Technologies is closely tied to two stories developing at the same time.
The first is the established iCRO business, which has demonstrated increasing backlog and continued revenue generation. The second is the eyonis® platform, where regulatory milestones in 2026 have moved the company closer to commercial deployment.
The June 2026 capital increase also strengthened the company’s financial resources, reducing some of the near-term financing pressure that can affect smaller growth companies.
However, investors should distinguish between potential and proven financial performance. The success of eyonis® still depends on commercial execution, while the company remains loss-making.
The next financial updates will therefore be important for assessing whether the improving operational picture is translating into stronger revenue, margins and long-term financial sustainability.
FAQs About Median Technologies Bourse
What is the Median Technologies stock ticker?
Median Technologies trades under the ticker ALMDT on Euronext Growth. Its ISIN is FR0011049824.
Where is Median Technologies listed?
Median Technologies is listed on Euronext Growth, giving investors access to the company’s shares through the European equity market.
What does Median Technologies do?
The company develops AI-powered medical imaging technologies and provides imaging services for pharmaceutical and biotechnology companies conducting clinical trials. Its eyonis® portfolio focuses on AI-based early cancer diagnosis.
What is eyonis® LCS?
eyonis® LCS is an AI-powered medical device developed for lung cancer screening. It received FDA 510(k) clearance and CE marking in 2026, supporting its commercialization in the United States and European Economic Area.
Is Median Technologies profitable?
Median Technologies was still reporting losses, although its operating loss decreased in 2025. Investors are therefore watching revenue growth, iCRO profitability and the future commercial contribution of eyonis®.
What is the main growth opportunity for Median Technologies?
The company’s major potential growth drivers include continued expansion of iCRO services and the commercialization of eyonis® products for early cancer diagnosis.
Is Median Technologies a high-risk stock?
ALMDT should be considered a higher-risk growth stock because of its relatively small market capitalization, historical share-price volatility, continuing losses and dependence on successful commercialization of new technologies.
Conclusion
Median Technologies bourse represents a developing healthcare technology story rather than a traditional mature company. Its ALMDT shares combine an established iCRO imaging-services business with the potentially transformative eyonis® AI medical-device portfolio.
The company has entered the second half of 2026 with a record iCRO backlog, a significantly stronger cash position and important regulatory achievements for eyonis® LCS.
At the same time, investors should remain aware of the risks surrounding profitability, dilution, commercialization and share-price volatility. For anyone following ALMDT, the most important indicators to watch are iCRO revenue, backlog growth, operating margins, cash usage, eyonis® commercialization and upcoming financial results.
Learn About: fundfireinsight.com
